AZ claims FDA okay for Brilinta in coronary artery disease p...

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary a

BMS gets FDA nod for ozanimod, but launch will be delayed

Celgene scores FDA okay for thalassaemia drug Reblozyl

Biogen bags FDA okay for Tecfidera follow-up Vumerity

Merck, Eisai get triple approvals for Keytruda/Lenvima combi...

J&J gets Stelara okay in Europe for ulcerative colitis